{'52WeekChange': 0.92361474,
 'SandP52WeekChange': None,
 'address1': 'Kalvebod Brygge 43',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 35.09,
 'askSize': 800,
 'averageDailyVolume10Day': 654900,
 'averageVolume': 1025619,
 'averageVolume10days': 654900,
 'beta': 0.52093,
 'beta3Year': None,
 'bid': 35.08,
 'bidSize': 1400,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Copenhagen',
 'companyOfficers': [],
 'country': 'Denmark',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 35.31,
 'dayLow': 34.56,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 2.736,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 22839216128,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 33.12343,
 'fiftyTwoWeekHigh': 36.63,
 'fiftyTwoWeekLow': 16.24,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 642653890,
 'forwardEps': 2.45,
 'forwardPE': 14.3265295,
 'fromCurrency': None,
 'fullTimeEmployees': 579,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.03997,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1525132800,
 'lastSplitFactor': '5:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/genmab.com',
 'longBusinessSummary': 'Genmab A/S, a biotechnology company, develops '
                        'antibody therapeutics for the treatment of cancer '
                        'primarily in Denmark. The company markets DARZALEX, a '
                        'human IgG1k monoclonal antibody for the treatment of '
                        'patients with multiple myeloma (MM); and Arzerra, a '
                        'human IgG1k monoclonal antibody for the treatment of '
                        'chronic lymphocytic leukemia (CLL). Its products '
                        'under development include Ofatumumab to treat CLL and '
                        'multiple sclerosis; Daratumumab to treat MM, natural '
                        'killer/T-cell lymphoma, and amyloidosis; Tisotumab '
                        'vedotin for treating cervical, ovarian, and solid '
                        'cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for '
                        'treating solid cancers; and DuoBody-CD3xCD20 for the '
                        "treatment of B-cell malignancies. The company's "
                        'products under development also comprise Teprotumumab '
                        "for the treatment of Graves' orbitopathy; "
                        'Camidanlumab tesirine (ADCT-301) to treat lymphoma, '
                        'solid tumors, and acute myeloid leukemia (AML); '
                        'HuMax-IL8 (BMS-986253) for treating advanced cancers; '
                        'JNJ-61186372 for the treatment of non-small-cell lung '
                        'cancer; JNJ-63709178 to treat AML; JNJ-64007957 and '
                        'JNJ-64407564 for MM; and Lu AF82422 for treating '
                        "Parkinson's disease. In addition, it has "
                        'approximately 20 active pre-clinical programs, '
                        'including naked, bispecific, and immune effector '
                        'function enhanced antibodies. The company has a '
                        'commercial license and collaboration agreement with '
                        'Seattle Genetics, Inc. to co-develop tisotumab '
                        'vedotin, an antibody-drug conjugate; and a strategic '
                        'collaboration agreement with Tempus to advance '
                        'various disease targets and biomarkers, as well as '
                        'Rentschler Biopharma SE. It also has a collaboration '
                        'agreement with Immatics Biotechnologies GmbH to '
                        'research and develop next-generation bispecific '
                        'immunotherapies for treating multiple cancer '
                        'indications; CureVac AG for the research and '
                        'development of differentiated mRNA-based antibody '
                        'products; and Tavotek Biotherapeutics and AbbVie. '
                        'Genmab A/S was founded in 1999 and is based in '
                        'Copenhagen, Denmark.',
 'longName': 'Genmab A/S',
 'market': 'us_market',
 'marketCap': 23225739264,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_665704',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 34.99,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '45 70 20 27 28',
 'previousClose': 35.76,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0.41696998,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 35.31,
 'regularMarketDayLow': 34.56,
 'regularMarketOpen': 34.99,
 'regularMarketPreviousClose': 35.76,
 'regularMarketPrice': 34.99,
 'regularMarketVolume': 1732613,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 651827008,
 'sharesPercentSharesOut': 0.0014,
 'sharesShort': 889516,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 840786,
 'shortName': 'Genmab A/S',
 'shortPercentOfFloat': None,
 'shortRatio': 0.72,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'GMAB',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 26.117914,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '5594dda7-7736-3abc-bcfd-5fa676c317ff',
 'volume': 1732613,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.genmab.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1560'}